LENMELDY

What this means for you

Not registered yet, but its 05 Jun 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98028058

Mark type

Stylized text

Filed

05 Jun 2023

Published for opposition

02 Apr 2024

Attorney of record

Michael J. Belliveau

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of orphan diseases, namely, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders; Chemical preparations for pharmaceutical or medical purposes for use in gene therapy for the treatment of orphan diseases, namely, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders; Medicinal preparations for the treatment of orphan diseases, namely, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders

Owner

• Orchard Therapeutics (Europe) Limited, London, GB
• Orchard Therapeutics (Europe) Limited, London, GB

Prosecution history

• 03 Dec 2025 — SOU TEAS EXTENSION RECEIVED
• 03 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
• 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 03 Jun 2025 — SOU EXTENSION 2 GRANTED
• 03 Jun 2025 — SOU EXTENSION 2 FILED
• 03 Jun 2025 — SOU TEAS EXTENSION RECEIVED
• 03 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 03 Dec 2024 — SOU EXTENSION 1 GRANTED
• 03 Dec 2024 — SOU EXTENSION 1 FILED
• 03 Dec 2024 — SOU TEAS EXTENSION RECEIVED
• 04 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 02 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 02 Apr 2024 — PUBLISHED FOR OPPOSITION
• 13 Mar 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 26 Feb 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER